Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

Clinical and neurobiological factors in the management of treatment refractory attention-deficit hyperactivity disorder

Authors
Shim, Se-HoonYoon, Hee-JungBak, JeongjaeHahn, Sang-WooKim, Yong-Ku
Issue Date
3-10월-2016
Publisher
PERGAMON-ELSEVIER SCIENCE LTD
Keywords
Attention deficit hyperactivity disorder; Methylphenidate; Atomoxetine; Pharmacogenetics; Neuroimaging; Treatment response
Citation
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, v.70, pp.237 - 244
Indexed
SCIE
SCOPUS
Journal Title
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
Volume
70
Start Page
237
End Page
244
URI
https://scholar.korea.ac.kr/handle/2021.sw.korea/87212
DOI
10.1016/j.pnpbp.2016.04.007
ISSN
0278-5846
Abstract
Attention-deficit/hyperactivity disorder (ADHD) is a highly prevalent mental disorder of childhood, which often continues into adolescence and adulthood. Stimulants such as methylphenidate (MPH) and non-stimulants such as atomoxetine are effective medications for the treatment of ADHD. However, about 30% of patients do not respond to these medications. Pharmacological treatment for ADHD, although highly effective, is associated with marked variabilities in clinical response, optimal dosage needed and tolerability. This article provides an overview of up-to-date knowledge regarding the clinical and neurobiological factors which contribute to and help predict treatment-refractory ADHD. Pharmacogenetic, pharmacogenomics and neuroimaging studies are still controversial with respect to determining the associations between response to medication and genetic factors, thereby resulting in hypotheses that differences in the genetic factors and neuroimaging findings contribute to treatment outcome. Much research on the potential role of genotype in pharmacological effects has focused on the catecholaminergic gene related to executive functions. Many neuroimaging studies have also reported a relationship between treatment response and common patterns of brain structure or activity according to various genetic polymorphisms. When children, adolescents and adults with ADHD do not respond to MPH, we should consider additional pharmacological options, including other classes of psychostimulants, the nonstimulant atomoxetine, bupropion, tricyclic antidepressant, clonidine, guanfacine and lisdexamphetamine. Prudent choice of an appropriate medication and active engagement of children, parents, and teachers in daily management may help to ensure long-term adherence. Therefore, additional research might help to optimize the treatment of children, adolescents and adults with ADHD and to find new options for the treatment of patients who do not respond to stimulants and the other medications. Because these findings should be interpreted cautiously, further studies are needed to elucidate these issues more clearly. (C) 2016 Elsevier Inc. All rights reserved.
Files in This Item
There are no files associated with this item.
Appears in
Collections
College of Medicine > Department of Medical Science > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Kim, Yong Ku photo

Kim, Yong Ku
의과대학 (의학과)
Read more

Altmetrics

Total Views & Downloads

BROWSE